Neurology and Neurosurgery - Global Neurology Academy

257-272 of 499

Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
On the Frontlines of Schizophrenia
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
Steven Paul, MD
- Steven Paul, MD
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiers
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Maxwell H. Levy, MD
- Maxwell H. Levy, MD
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
NeuroFrontiers
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
Steven Paul, MD
- Steven Paul, MD
Navigating Myasthenia Gravis in Adolescents and Young Adults
Navigating Myasthenia Gravis in Adolescents and Young Adults
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
Jonathan Strober, MD
- Jonathan Strober, MD
Spotting the Signs: Early Identification and Management of Schizophrenia
Spotting the Signs: Early Identification and Management of Schizophrenia
On the Frontlines of Schizophrenia
Spotting the Signs: Early Identification and Management of Schizophrenia
Desiree Matthews, PMHNP-BC
- Desiree Matthews, PMHNP-BC
Quality of Life in Schizophrenia Patients: Challenges and Practical Approaches to Care
Quality of Life in Schizophrenia Patients: Challenges and Practical Approaches to Care
On the Frontlines of Schizophrenia
Quality of Life in Schizophrenia Patients: Challenges and Practical Approaches to Care
Desiree Matthews, PMHNP-BC
- Desiree Matthews, PMHNP-BC
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Gil I. Wolfe MD, FAAN
- Gil I. Wolfe MD, FAAN
Challenges in DMD: Understanding the Height Factor
Challenges in DMD: Understanding the Height Factor
NeuroFrontiers
Challenges in DMD: Understanding the Height Factor
Schizophrenia Care: Improving Social Cognition and Motivation
Schizophrenia Care: Improving Social Cognition and Motivation
On the Frontlines of Schizophrenia
Schizophrenia Care: Improving Social Cognition and Motivation
Michael Green, PhD
- Michael Green, PhD
The Evolving gMG Treatment Landscape
The Evolving gMG Treatment Landscape
NeuroFrontiers
The Evolving gMG Treatment Landscape
Henry Kaminski, MD
- Henry Kaminski, MD
FcRn Inhibitors: A Potential New Targeted Therapy Option
FcRn Inhibitors: A Potential New Targeted Therapy Option
NeuroFrontiers
FcRn Inhibitors: A Potential New Targeted Therapy Option
Nicholas J. Silvestri, MD
- Nicholas J. Silvestri, MD
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NeuroFrontiers
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NeuroFrontiers
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiers
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
NeuroFrontiers
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Thomas Karikari, PhD
- Thomas Karikari, PhD
Amyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
Amyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
NeuroFrontiers
Amyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
Michele Longo, MD
- Michele Longo, MD

17/11